Skip to main content

2023 Year in Review

This year was a notable year for the Angelman syndrome community — one filled with excitement, some growing pains, frustrations, but most importantly, progress towards potential therapeutics for individuals living with Angelman syndrome.

Here’s a review of our year:

  • NIH announced a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases, Angelman syndrome being one of them.

  • FAST partnered with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome.

  • Ionis Pharmaceuticals and Ultragenyx Pharmaceuticals provided promising updates on their respective investigational ASO clinical trials.

  • FAST has grown its staff, hiring four critical new staffers to support the operationalization of our mission.

  • The 16th Annual Global Science Summit & Gala was a success for so many reasons — save the date for next year’s event: Nov 8-9, 2024 in Orlando, FL!

  • We added FAST Poland to our list of global chapters!

  • Our community did an amazing job raising funds through social media, hosting events, and peer-to-peer campaigns. We look forward to another successful year of Cure Angelman Now (CAN) fundraising — stay tuned in January 2024 for more details!

We could not do what we do without you. We wish you and your family a safe and happy holiday season. See you back here in 2024 when we hit the ground running!


The FAST Board & Staff